Speaker
Faiez Zannad
University of Lorraine,
Vandoeuvre-Les-Nancy
(France )
Specialities :
Chronic Heart Failure
,
Pharmacology and Pharmacotherapy, Hypertension, Risk Factors and Prevention
88 presentations
MD, PhD, Cardiologist, Clinical pharmacologist. Trained at Université de Lorraine, Université of Lyon, France and Medical Research Council (Oxford, UK). Currently, Emeritus Professor of Therapeutics at Université de Lorraine, France.
As a trialist, he contributed to building the evidence supporting modern HF therapy, notably with beta-blockers, RAASi and MRAs. As a clinical scientist his work focuses on fibrosis and biomarkers.
He has served as Chairman of the French Society of Hypertension, of the ESC Working Group on Pharmacology and Drug Therapy. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop with meetings in Paris, Washington DC, in Asia and the Middle East.
Professor Zannad published more than 750 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA and served as an Eugene Braunwald Scholar in 2019 at Harvard Medical School.
88
presentations
from this speaker
EMPEROR-Reduced.
Event :
ESC Asia 2020
Session :
Trial Focus - EMPEROR-Reduced
Speaker : F
Zannad
(Vandoeuvre,FR), CS
Lam
(Singapore,SG), Y
Sakata
(Sendai,JP)
Panel discussion
Event :
ESC Congress 2020
Session :
New evidence on sodium-glucose transport protein 2 inhibitors therapy in heart failure patients
Speaker : G
Filippatos
(Athens,GR), J
Butler
(Atlanta,US), M
Packer
(Dallas,US), S
Anker
(Berlin,DE), F
Zannad
(Vandoeuvre,FR)
Organised by Charité IME, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant
SGLT2 inhibitors in HFrEF, a meta-analytical approach.
Event :
ESC Congress 2020
Session :
New evidence on sodium-glucose transport protein 2 inhibitors therapy in heart failure patients
Speaker : F
Zannad
(Vandoeuvre,FR)
Organised by Charité IME, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant
Panel discussion
Event :
ESC Congress 2019
Session :
Discussing the opportunities for SGLT2 in clinical cardiology
Speaker : F
Zannad
(Vandoeuvre,FR), TF
Luscher
(London,GB), C
Wanner
(Wuerzburg,DE), J
Deanfield
(,GB)
Organised by PACE-CME, supported with an educational grant provided by Boehringer-Ingelheim/Lilly
Potassium and heart failure.
Event :
Webinar 2019
Session :
HFA Webinars 2019
Speaker : S
Anker
(Berlin,DE), J
Cleland
(Glasgow,GB), M
Lainscak
(Murska Sobota,SI), F
Zannad
(Vandoeuvre,FR)
Welcome and introduction
Event :
ESC Congress 2019
Session :
New approach for worsening chronic heart failure
Speaker : F
Zannad
(Vandoeuvre,FR)
COMMANDER.
Event :
ESC Congress 2018
Session :
Meet the trialist - COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Speaker : F
Zannad
(Vandoeuvre,FR)
In patients with diabetes
Event :
Heart Failure 2018
Session :
Prevention of heart failure
Speaker : F
Zannad
(Vandoeuvre,FR)
Opening and remarks.
Event :
Heart Failure 2018
Session :
Expanding the evidence in heart failure patients
Speaker : F
Zannad
(Vandoeuvre,FR)
Chair's introduction.
Event :
Heart Failure 2017
Session :
New opportunities for an old problem: lowering potassium to maximize heart failure therapy
Speaker : F
Zannad
(Vandoeuvre,FR)
Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca
Diagnosis and prognosis.
Event :
Heart Failure 2017
Session :
What a busy clinician should know about heart failure with preserved ejection fraction
Speaker : F
Zannad
(Vandoeuvre,FR)
Experience with empagliflozin: insights from practice.
Event :
ESC Congress 2017
Session :
Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
Speaker : N
Marx
(Aachen,DE), D
McGuire
(Dallas,US), F
Zannad
(Vandoeuvre,FR), JA
Udell
(Toronto,CA)
Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
Oral anticoagulation.
Event :
Heart Failure 2017
Session :
How to manage atrial fibrillation and low ejection fraction?
Speaker : F
Zannad
(Vandoeuvre,FR)
Panel Q&A / Discussion.
Event :
Heart Failure 2017
Session :
New opportunities for an old problem: lowering potassium to maximize heart failure therapy
Speaker : F
Zannad
(Vandoeuvre,FR), J
Cleland
(Glasgow,GB), P
Van Der Meer
(Groningen,NL)
Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca
Summary and conclusions.
Event :
Heart Failure 2017
Session :
Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
Speaker : F
Zannad
(Vandoeuvre,FR)
Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma
Summary and key learnings.
Event :
Heart Failure 2017
Session :
Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
Speaker : F
Zannad
(Vandoeuvre,FR)
Welcome and introduction.
Event :
Heart Failure 2017
Session :
Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
Speaker : JJV
McMurray
(Glasgow,GB), F
Zannad
(Vandoeuvre,FR)
Introduction.
Event :
Heart Failure 2016
Session :
Implications of novel treatment strategies for the management of hyperkalemia in heart failure
Speaker : F
Zannad
(Vandoeuvre,FR)
Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca
Is it really beneficial?
Event :
Heart Failure 2016
Session :
Exercise training: for whom, when and how?
Speaker : F
Zannad
(Vandoeuvre,FR)
NOACs studied in atrial fibrillation.
Event :
Heart Failure 2016
Session :
What heart failure specialists can learn from trials in other disease areas
Speaker : F
Zannad
(Vandoeuvre,FR)
Panel discussion.
Event :
Heart Failure 2016
Session :
Optimizing RAAS inhibition in heart failure: novel treatment considerations for the management of hyperkalemia
Speaker : F
Zannad
(Vandoeuvre,FR), GMC
Rosano
(London,GB)
Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca
Questions & answers session.
Event :
Heart Failure 2016
Session :
Oral anticoagulation in patients with heart failure: today and tomorrow
Speaker : F
Zannad
(Vandoeuvre,FR), D
van Veldhuisen
(Groningen,NL)
RAAS inhibition in heart failure: corner stone of therapy & potassium homeostasis.
Event :
Heart Failure 2016
Session :
Optimizing RAAS inhibition in heart failure: novel treatment considerations for the management of hyperkalemia
Speaker : F
Zannad
(Vandoeuvre,FR)
Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca
Vagal nerve stimulation
Event :
ESC Congress 2016
Session :
What's new in chronic heart failure devices
Speaker : F
Zannad
(Vandoeuvre,FR)
Welcome and introduction.
Event :
Heart Failure 2016
Session :
Oral anticoagulation in patients with heart failure: today and tomorrow
Speaker : F
Zannad
(Vandoeuvre,FR)
Chairperson’s welcome and introduction.
Event :
Heart Failure 2015
Session :
Novel oral anticoagulant use in patients with heart failure: present and future perspectives
Speaker : F
Zannad
(Vandoeuvre,FR)
Sponsored by Bayer Healthcare
Heart failure polypharmacy.
Event :
ESC Congress 2015
Session :
Important drug interactions: what the cardiologist should know
Speaker : F
Zannad
(Vandoeuvre,FR)
Heart failure polypharmacy.
Event :
ESC Congress 2014
Session :
Important drug interactions - what you should know!
Speaker : F
Zannad
(Vandoeuvre,FR)
